Hôpital Beaujon
Hôpital Beaujon
Clichy, France11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | Digestive System Diseases, Infections, RNA Virus Infections, hepatitis, hepatitis D virus infection, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 3 | 2026-10-08 | NCT07200908 | |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-10-08 | NCT07165028 | |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Metabolic Dysfunction Associated Steatohepatitis | Recruiting | Phase 3 | 2026-10-01 | NCT06632457 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy | Extrapulmonary Neuroendocrine Cancer (epNEC) | Recruiting | Phase 3 | 2026-09-29 | NCT07544654 | |
| A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial). | Acute-On-Chronic Liver Failure, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute liver failure, cirrhosis of liver, liver disorder, liver failure | Recruiting | Phase 2 | 2026-09-11 | NCT05895136 | |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder | Recruiting | Phase 3 | 2026-05-13 | NCT05677971 | |
| Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma Recurrent; Liver Transplant; Systemic Treatment | Recruiting | Phase 2 | 2026-03-10 | NCT06254248 | |
| Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Infections, Mosquito-Borne Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, hereditary spherocytosis, inherited hemoglobinopathy, malaria, parasitic infectious disease, protozoa infectious disease, sickle cell disease, vector-borne disease | Recruiting | Not stated | 2025-09-15 | NCT06418256 | |
| Retrospective Study to Assess the Evolution of MRI or CT Lesions in Treated CNS Nocardiosis | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, nocardiosis | Not yet recruiting | Not stated | 2025-09-12 | NCT07013006 | |
| Peer Support in Alcohol Dependence | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, psychiatric disorder, substance-related disorder | Not yet recruiting | Not applicable | 2024-06-11 | NCT06381609 |